News
NeuroVoices: Orrin Devinsky, MD, on Unanswered Questions With SUDEP, Heart Rate Variability
November 24th 2021The director of the Comprehensive Epilepsy Center at NYU Langone discussed the large-scale impact heart rate variability has on preventing SUDEP and the unanswered questions that remain.
AAN Issues Statement on Ethical Considerations for Aducanumab Use in Alzheimer Disease
November 23rd 2021The American Academy of Neurology’s statement touched on the roles played by the principles of beneficence, nonmaleficence, justice, and patient autonomy as it relates to the clinical use of the therapy for this patient population.
Role Heart Rate Variability Plays in SUDEP Research, Prevention: Orrin Devinsky, MD
November 23rd 2021The director of the Comprehensive Epilepsy Center at NYU Langone discussed the necessary steps in validating and utilizing heart rate variability as a biomarker for SUDEP. [WATCH TIME: 3 minutes]
Incidence of Poststroke Dementia Remains Highly Prevalent
November 23rd 2021The risk of dementia was substantial and front-loaded following stroke, with the 1-year prevalence similar to the estimate for dementia at any time point. The findings indicate a need for greater engagement between stroke and dementia care.
The Therapeutic Space for People Living With Headache After COVID-19 Infection
November 22nd 2021Although headache and COVID-19 have been linked together in the literature, more studies are needed to better understand the pathophysiology of these headaches and to determine the best treatment options.
Realistic Outlook for Mesenchymal Stem Cells, Other Treatments in Progressive MS: Jeffrey Cohen, MD
November 22nd 2021The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed when clinicians should anticipate new therapies to treat progressive MS. [WATCH TIME: 2 minutes]
Prestroke Glycemic Control Associated With Subsequent Risk of Composite Vascular Events
November 22nd 2021The optimal range of HbA1c between 6.8% and 7.0% at admission was estimated to have the minimum risk for composite vascular events and stroke recurrence, with notably different levels according to stroke subtype.
Next Steps, Future Development of FUS Technology in Alzheimer Disease: Ali Rezai, MD
November 22nd 2021The executive chair of the Rockefeller Neuroscience Institute at West Virginia University discussed the potential of focused ultrasound for patients with AD, as well as key takeaways for clinicians from a recent study. [WATCH TIME: 5 minutes]
AUPN Leadership Minute Episode 16: Turning Your Clinic Into a Source of Scholarly Activity
November 20th 2021Episode 16 of the AUPN Leadership Minute features Rohit Das, MD, of UT Southwestern Medical Center; and Selim R. Benbadis, MD, FAAN, FACNS, FAES, University of South Florida Morsani College of Medicine. [WATCH TIME: 4 minutes]
Evaluating Early Data on Focused Ultrasound for Patients With Alzheimer Disease
November 19th 2021Ali Rezai, MD, executive chair at the Rockefeller Neuroscience Institute at West Virginia University, outlined early data from a clinical trial utilizing focused ultrasound to open the blood-brain barrier in patients with mild AD.
Neflamapimod Displays Robust Efficacy in Pure Lewy Body Dementia Pathology
November 19th 2021The magnitude of neflamapimod’s effect on several efficacy measures proved to be consistent with the mechanism of action and prior preclinical data, with p-tau181 data suggesting a stronger effect on nonmixed Lewy body pathology.
Heart Rate Variability’s Role in Potential SUDEP-Predicting Modalities: Orrin Devinsky, MD
November 19th 2021The director of the Comprehensive Epilepsy Center at NYU Langone provided insight on whether a newly discovered biomarker can play a role in the creation of modalities to detect SUDEP risk. [WATCH TIME: 3 minutes]
